Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CPS1 | P31327 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859365 | 0.84 | CPS1 (0.56) | CPS1NPC1 | |
| SCHEMBL5057119 | 0.84 | KDM4E (0.69) | KDM4EMAOBPARP10NPC1 | |
| SCHEMBL2100809 | 0.84 | CPS1 (0.56) | CPS1NPC1 | |
| SCHEMBL22286220 | 0.84 | MAOB (0.44) | CPS1MAOBMAOAPARP10PARP15 | |
| SCHEMBL13366264 | 0.82 | RARA (0.55) | KDM4ECPS1MAOBMAOAFFAR1 | |
| SCHEMBL14356128 | 0.82 | MAOB (0.66) | KDM4ECPS1MAOBMAOA | |
| SCHEMBL5264249 | 0.82 | MAOB (0.43) | MAOBMAOAPARP10PARP15FFAR1 | |
| SCHEMBL11757434 | 0.81 | KDM4E (0.53) | KDM4EPARP10FFAR1FFAR4NPC1 | |
| SCHEMBL22286235 | 0.80 | PARP10 (0.64) | PARP10PARP15FFAR1FFAR4 | |
| SCHEMBL5460586 | 0.80 | PARP10 (0.56) | MAOBMAOAPARP10PARP15NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365212-B2 | Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions | ZACH SYSTEM S.P.A. (IT) | 2008-04-29 | — | — | US | disclosed |
| EP-1673375-B1 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG SIPSY (FR) | 2007-08-01 | — | — | EP | disclosed |
| US-20070055068-A1 | Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions | PPG-SIPSY (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-0736509-B1 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-6156940-A | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6025531-A | REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5801280-A | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0736509-A2 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-09 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055068-A1 | Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions | OGFR, OXSR1, OTC | KDM4E 1887/4885CPS1 1466/4885MAOB 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.